Yashiro et al. review in detail the regulatory factors of ILC2s identified in mice, further discussing the role of ILC2s in various diseases as well as in allergies.

Iwata et al. summarize recent findings on the characteristics and functions of human lung ILC2s, describing their clinical significance in bronchial asthma.

Imai describes ILC2s in the skin, which have a completely different activation mechanism than ILC2s in the lung and discusses their potential as targets for monoclonal antibody therapy. Because ILC2s are tissue-resident cells with different phenotypes depending on the tissue, the characteristics of ILC2s in each tissue must be considered when determining therapeutic targets to suppress ILC2s.